Alnylam Historical Income Statement

ALNY Stock

USD 271.02 1.81 0.67%

Historical analysis of Alnylam Pharmaceuticals income statement accounts such as Interest Expense of 149 M, Other Operating Expenses of 2.5 B or Research Development of 1.2 B can show how well Alnylam Pharmaceuticals performed in making a profits. Evaluating Alnylam Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Alnylam Pharmaceuticals's future profits or losses.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Alnylam Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Alnylam Pharmaceuticals is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alnylam Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.

About Alnylam Income Statement Analysis

Alnylam Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Alnylam Pharmaceuticals shareholders. The income statement also shows Alnylam investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Alnylam Pharmaceuticals Income Statement Chart

At this time, Alnylam Pharmaceuticals' Reconciled Depreciation is fairly stable compared to the past year.

Other Operating Expenses Research Development Total Operating Expenses Selling General Administrative

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Alnylam Pharmaceuticals. It is also known as Alnylam Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Alnylam Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Alnylam Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alnylam Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.At this time, Alnylam Pharmaceuticals' Reconciled Depreciation is fairly stable compared to the past year.

	2022	2023	2024	2025 (projected)
Gross Profit	868.6M	1.5B	1.9B	2.0B
Total Revenue	1.0B	1.8B	2.2B	2.4B

Gross Profit Total Revenue

Alnylam Pharmaceuticals income statement Correlations

	Depreciation And Amortization	Interest Expense	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Total Operating Expenses	Net Income	Income Tax Expense	Selling General Administrative	Total Revenue	Gross Profit	Cost Of Revenue	Income Before Tax	Total Other Income Expense Net	Net Income From Continuing Ops	Non Operating Income Net Other	Non Recurring	Interest Income	Net Interest Income	Reconciled Depreciation	Extraordinary Items
Depreciation And Amortization		0.94	0.9	-0.29	-0.4	0.91	-0.34	0.9	-0.45	0.63	0.89	0.82	0.82	0.06	-0.38	-0.22	-0.45	-0.63	-0.52	0.7	-0.5	0.88	-0.52
Interest Expense	0.94		0.94	-0.39	-0.52	0.94	-0.48	0.95	-0.59	0.66	0.95	0.82	0.82	-0.09	-0.51	-0.36	-0.59	-0.66	-0.49	0.65	-0.66	0.92	-0.49
Other Operating Expenses	0.9	0.94		-0.27	-0.41	0.99	-0.36	1.0	-0.45	0.77	0.99	0.93	0.93	0.06	-0.36	-0.23	-0.44	-0.74	-0.64	0.83	-0.51	0.83	-0.64
Operating Income	-0.29	-0.39	-0.27		0.93	-0.34	0.94	-0.32	0.95	0.2	-0.3	0.1	0.11	0.17	0.96	0.2	0.95	-0.25	-0.27	0.17	0.36	-0.38	-0.27
Ebit	-0.4	-0.52	-0.41	0.93		-0.47	1.0	-0.46	0.95	0.02	-0.44	-0.05	-0.04	0.15	0.94	0.14	0.95	-0.07	-0.17	0.04	0.44	-0.48	-0.17
Research Development	0.91	0.94	0.99	-0.34	-0.47		-0.42	1.0	-0.5	0.72	0.98	0.9	0.89	0.12	-0.42	-0.22	-0.5	-0.7	-0.61	0.81	-0.49	0.82	-0.61
Ebitda	-0.34	-0.48	-0.36	0.94	1.0	-0.42		-0.41	0.94	0.07	-0.39	0.0	0.01	0.16	0.93	0.13	0.94	-0.11	-0.2	0.08	0.42	-0.44	-0.2
Total Operating Expenses	0.9	0.95	1.0	-0.32	-0.46	1.0	-0.41		-0.49	0.75	1.0	0.91	0.91	0.05	-0.41	-0.23	-0.49	-0.71	-0.62	0.81	-0.51	0.83	-0.62
Net Income	-0.45	-0.59	-0.45	0.95	0.95	-0.5	0.94	-0.49		0.07	-0.48	-0.1	-0.1	0.14	0.99	0.4	1.0	0.02	-0.18	0.04	0.58	-0.58	-0.18
Income Tax Expense	0.63	0.66	0.77	0.2	0.02	0.72	0.07	0.75	0.07		0.77	0.86	0.87	-0.09	0.18	0.17	0.07	-0.63	-0.89	0.88	-0.15	0.43	-0.89
Selling General Administrative	0.89	0.95	0.99	-0.3	-0.44	0.98	-0.39	1.0	-0.48	0.77		0.91	0.91	-0.02	-0.39	-0.23	-0.48	-0.71	-0.62	0.81	-0.53	0.84	-0.62
Total Revenue	0.82	0.82	0.93	0.1	-0.05	0.9	0.0	0.91	-0.1	0.86	0.91		1.0	0.13	-0.01	-0.2	-0.1	-0.86	-0.76	0.93	-0.38	0.71	-0.76
Gross Profit	0.82	0.82	0.93	0.11	-0.04	0.89	0.01	0.91	-0.1	0.87	0.91	1.0		0.13	0.0	-0.19	-0.09	-0.85	-0.77	0.93	-0.37	0.7	-0.77
Cost Of Revenue	0.06	-0.09	0.06	0.17	0.15	0.12	0.16	0.05	0.14	-0.09	-0.02	0.13	0.13		0.15	-0.03	0.15	-0.24	-0.07	0.13	0.08	-0.09	-0.07
Income Before Tax	-0.38	-0.51	-0.36	0.96	0.94	-0.42	0.93	-0.41	0.99	0.18	-0.39	-0.01	0.0	0.15		0.43	0.99	-0.05	-0.28	0.14	0.56	-0.54	-0.28
Total Other Income Expense Net	-0.22	-0.36	-0.23	0.2	0.14	-0.22	0.13	-0.23	0.4	0.17	-0.23	-0.2	-0.19	-0.03	0.43		0.41	0.48	-0.18	0.06	0.67	-0.47	-0.18
Net Income From Continuing Ops	-0.45	-0.59	-0.44	0.95	0.95	-0.5	0.94	-0.49	1.0	0.07	-0.48	-0.1	-0.09	0.15	0.99	0.41		0.02	-0.19	0.05	0.58	-0.58	-0.19
Non Operating Income Net Other	-0.63	-0.66	-0.74	-0.25	-0.07	-0.7	-0.11	-0.71	0.02	-0.63	-0.71	-0.86	-0.85	-0.24	-0.05	0.48	0.02		0.55	-0.76	0.39	-0.59	0.55
Non Recurring	-0.52	-0.49	-0.64	-0.27	-0.17	-0.61	-0.2	-0.62	-0.18	-0.89	-0.62	-0.76	-0.77	-0.07	-0.28	-0.18	-0.19	0.55		-0.81	0.02	-0.25	1.0
Interest Income	0.7	0.65	0.83	0.17	0.04	0.81	0.08	0.81	0.04	0.88	0.81	0.93	0.93	0.13	0.14	0.06	0.05	-0.76	-0.81		-0.02	0.48	-0.81
Net Interest Income	-0.5	-0.66	-0.51	0.36	0.44	-0.49	0.42	-0.51	0.58	-0.15	-0.53	-0.38	-0.37	0.08	0.56	0.67	0.58	0.39	0.02	-0.02		-0.76	0.02
Reconciled Depreciation	0.88	0.92	0.83	-0.38	-0.48	0.82	-0.44	0.83	-0.58	0.43	0.84	0.71	0.7	-0.09	-0.54	-0.47	-0.58	-0.59	-0.25	0.48	-0.76		-0.25
Extraordinary Items	-0.52	-0.49	-0.64	-0.27	-0.17	-0.61	-0.2	-0.62	-0.18	-0.89	-0.62	-0.76	-0.77	-0.07	-0.28	-0.18	-0.19	0.55	1.0	-0.81	0.02	-0.25

Click cells to compare fundamentals

Alnylam Pharmaceuticals Account Relationship Matchups

Alnylam Pharmaceuticals income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Depreciation And Amortization	34.8M	47.6M	44.5M	54.1M	56.7M	59.5M
Interest Expense	84.5M	143.0M	156.0M	121.2M	141.9M	149.0M
Other Operating Expenses	1.3B	1.6B	1.8B	2.1B	2.4B	2.5B
Operating Income	(828.4M)	(708.7M)	(785.1M)	(282.2M)	(176.9M)	(185.7M)
Ebit	(771.1M)	(709.1M)	(971.0M)	(312.3M)	(235.5M)	(247.3M)
Research Development	654.8M	792.2M	883.0M	1.0B	1.1B	1.2B
Ebitda	(736.3M)	(661.6M)	(926.6M)	(258.2M)	(178.8M)	(187.8M)
Total Operating Expenses	1.2B	1.4B	1.7B	1.8B	2.1B	2.2B
Net Income	(858.3M)	(852.8M)	(1.1B)	(440.2M)	(278.2M)	(292.1M)
Income Tax Expense	2.7M	680K	4.2M	6.7M	99.2M	104.2M
Selling General Administrative	588.4M	620.6M	770.7M	795.6M	975.5M	1.0B
Total Revenue	492.9M	844.3M	1.0B	1.8B	2.2B	2.4B
Gross Profit	414.8M	704.1M	868.6M	1.5B	1.9B	2.0B
Cost Of Revenue	78.1M	140.1M	168.8M	310.4M	323.4M	186.7M
Income Before Tax	(855.6M)	(852.1M)	(1.1B)	(433.5M)	(178.9M)	(187.9M)
Total Other Income Expense Net	(27.2M)	(143.5M)	(341.9M)	(151.3M)	(2.1M)	(2.2M)
Net Income From Continuing Ops	(858.3M)	(852.8M)	(1.1B)	(440.2M)	(278.2M)	(292.1M)
Non Operating Income Net Other	54.2M	57.3M	(471K)	(186.0M)	(167.4M)	(159.0M)
Net Income Applicable To Common Shares	(886.1M)	(858.3M)	(852.8M)	(1.1B)	(1.0B)	(967.1M)
Interest Income	11.8M	1.6M	24.8M	95.6M	122.0M	128.1M
Tax Provision	2.7M	680K	4.2M	6.7M	(99.2M)	(94.3M)
Net Interest Income	(72.7M)	(141.4M)	(131.2M)	(25.7M)	(19.9M)	(20.9M)
Reconciled Depreciation	74.4M	89.7M	85.6M	97.0M	56.7M	65.7M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Alnylam Stock Analysis

When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Alnylam Historical Income Statement

About Alnylam Income Statement Analysis

Alnylam Pharmaceuticals Income Statement Chart

Other Operating Expenses

Total Operating Expenses

Alnylam Pharmaceuticals income statement Correlations

Alnylam Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Alnylam Pharmaceuticals income statement Accounts

Also Currently Popular

Additional Tools for Alnylam Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebitda	+ 1.0	Ebit
Total Operating Expenses	+ 1.0	Research Development
Selling General Administrative	+ 1.0	Total Operating Expenses
Net Income From Continuing Ops	+ 1.0	Net Income
Gross Profit	+ 1.0	Total Revenue

Extraordinary Items	- 0.89	Income Tax Expense
Non Recurring	- 0.89	Income Tax Expense
Non Operating Income Net Other	- 0.86	Total Revenue
Non Operating Income Net Other	- 0.85	Gross Profit
Extraordinary Items	- 0.81	Interest Income
Interest Income	- 0.81	Non Recurring